Ms. Diaz will initially attend all board of directors meetings in an advisory capacity. ERYTECH will nominate Ms. Diaz to serve as a voting board member in January in anticipation of the next general shareholders’ meeting.
Ms. Diaz has more than 20 years of experience in the global biopharmaceutical and biotechnology industry and has held management and executive positions at leading biopharmaceutical companies, including TESARO, Merck Serono, Biogen Idec and Pfizer.
With broad cross functional expertise in sales, medical affairs, marketing, new product planning, portfolio planning, strategic planning, and market access, Ms. Diaz currently serves as senior vice president, global commercial development at TESARO. She focuses on the development of commercialization strategies across therapeutic assets, evaluates the commercial impact of clinical development options, and assesses potential in-licensing opportunities. Prior to joining TESARO, she served as SVP, managed markets at EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, where she developed market access strategies and tactics for reimbursement by commercial and government payers across the EMD Serono portfolio.
Previously, Ms. Diaz also held the positions of SVP, head of oncology commercial, U.S. and VP, oncology marketing at EMD Serono, where she oversaw the commercial pre-launch efforts for EMD Serono’s oncology products. Ms. Diaz has held executive, management and/or line positions at other leading companies including Amylin Pharmaceuticals, Cancervax Corporation, Biogen Idec, Pfizer, and ParkeDavis Pharmaceuticals.
The Value of Diversity In Life Sciences
“Allene’s extensive experience in the biopharmaceutical industry, and oncology specifically, will be invaluable to us at this important stage of our clinical development,” said Gil Beyen, chief executive officer and chairman of the board of ERYTECH Pharma. “We thank everyone on the team at Coulter Partners for conducting such an outstanding search on our behalf. It is with great pleasure that we welcome Allene to our board of directors and we look forward to leveraging her strategic counsel as we work towards advancing our ERYCAPS technology platform-based products.”
“Coulter Partners has long recognized the value of diversity in the life science boardroom,” said Bianca Coulter, the search firm’s CEO. “It is refreshing to see that organizations in this fast-changing and innovative sector are no longer paying lip service to diversity in board composition, but are truly reaping the benefits of a board, whose depth and breadth of insight, perspective and experience can bring so much more to their corporate governance and business success.”
ERYTECH Pharma is a French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs.
According to Deloitte’s just released 2016 global sector outlook on life sciences, persistent talent shortages and the need to develop and retain employees with critical business and technology skill sets will continue to challenge global life sciences companies as they try to navigate a new world of work — one that requires a dramatic change in strategies for leadership, talent, and human resources.
“Our sector has changed beyond anyone’s expectations over the last two decades,” said Ms. Coulter. “We need to understand the appetites and needs of the major multinationals. This requires reach into all corners of the market. While our office network is growing, the key has been to have multilingual, multi-market experienced and connected researchers and consultants. Our team speaks many languages and has worked in all major bio-pharma markets and is organized as one P&L, to ensure collaborative information and experience sharing.”
Contributed by Dale M. Zupsansky, Managing Editor, Hunt Scanlon Media